Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:RCUS
CUSIPN/A
Phone510-694-6200
Debt
Debt-to-Equity RatioN/A
Current Ratio16.33
Quick Ratio16.33
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares44,460,000
Market Cap$525.92 million
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) issued its quarterly earnings results on Monday, August, 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.08. The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $1.30 million. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
3 brokers have issued 12 month price objectives for Arcus Biosciences' stock. Their forecasts range from $18.00 to $21.00. On average, they anticipate Arcus Biosciences' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 43.2% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.
What is the consensus analysts' recommendation for Arcus Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Cambrex (CBM), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Prestige Brands (PBH), Portola Pharmaceuticals (PTLA), G1 Therapeutics (GTHX), Mirati Therapeutics (MRTX), Pacira Pharmaceuticals (PCRX), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Enanta Pharmaceuticals (ENTA), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX) and Nabriva Therapeutics (NBRV).
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Dr. Terry Rosen Ph.D., Co-Founder, CEO & Director (Age 58)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 60)
- Ms. Jennifer Jarrett M.B.A., COO & CFO (Age 47)
- Mr. Steven Chan, VP of Fin., Corp. Controller & Principal Accounting Officer (Age 46)
- Dr. Stephen Young Ph.D., VP of Technology (Age 49)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.
When does the company's lock-up period expire?
Arcus Biosciences' lock-up period expires on Tuesday, September 11th. Arcus Biosciences had issued 8,000,000 shares in its IPO on March 15th. The total size of the offering was $120,000,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Has Arcus Biosciences been receiving favorable news coverage?
Media headlines about RCUS stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arcus Biosciences earned a daily sentiment score of 0.24 on Accern's scale. They also assigned news coverage about the company an impact score of 45.69 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Arcus Biosciences.
Who are Arcus Biosciences' major shareholders?
Arcus Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Partner Fund Management L.P. (1.73%), Hillhouse Capital Management Ltd. (1.73%), BlackRock Inc. (0.75%), Vident Investment Advisory LLC (0.35%), Baker BROS. Advisors LP (0.27%) and Platinum Investment Management Ltd. (0.12%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.
Which institutional investors are selling Arcus Biosciences stock?
Which institutional investors are buying Arcus Biosciences stock?
RCUS stock was acquired by a variety of institutional investors in the last quarter, including Hillhouse Capital Management Ltd., BlackRock Inc., Vident Investment Advisory LLC, Baker BROS. Advisors LP, Platinum Investment Management Ltd., Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and Lumina Fund Management LLC. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $13.27.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $525.92 million.
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
